Cargando…

Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure

BACKGROUND: Mucopolysaccharidosis type I (MPS I) is traditionally divided into three phenotypes: the severe Hurler (MPS I-H) phenotype, the intermediate Hurler-Scheie (MPS I-H/S) phenotype and the attenuated Scheie (MPS I-S) phenotype. However, there are no clear criteria for delineating the differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Ru, Minke H, Teunissen, Quirine GA, van der Lee, Johanna H, Beck, Michael, Bodamer, Olaf A, Clarke, Lorne A, Hollak, Carla E, Lin, Shuan-Pei, Rojas, Maria-Verónica Muñoz, Pastores, Gregory M, Raiman, Julian A, Scarpa, Maurizio, Treacy, Eileen P, Tylki-Szymanska, Anna, Wraith, J Edmond, Zeman, Jiri, Wijburg, Frits A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379958/ https://www.ncbi.nlm.nih.gov/pubmed/22524701 http://dx.doi.org/10.1186/1750-1172-7-22

Ejemplares similares

Diagnostic difficulties in patients with attenuated form of MPS VI
por: Opoka – Winiarska, V, et al.
Publicado: (2011)

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder
por: Wijburg, Frits A, et al.
Publicado: (2013)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Comparison of growth dynamics in different types of MPS: an attempt to explain the causes
por: Różdżyńska-Świątkowska, Agnieszka, et al.
Publicado: (2022)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: a MPS I case study
por: Węgrzyn, Grzegorz, et al.
Publicado: (2005)

Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry
por: Viskochil, David, et al.
Publicado: (2019)

“Missing mutations” in MPS I: Identification of two novel copy number variations by an IDUA‐specific in house MLPA assay
por: Jahic, Amir, et al.
Publicado: (2019)

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for MPS IIIA: a mixed methods approach
por: Lanar, Sally, et al.
Publicado: (2022)

The attenuated end of the phenotypic spectrum in MPS III: from late-onset stable cognitive impairment to a non-neuronopathic phenotype
por: Nijmeijer, Stephanie C. M., et al.
Publicado: (2019)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
por: Akyol, Mehmet Umut, et al.
Publicado: (2019)

Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance
por: Akyol, Mehmet Umut, et al.
Publicado: (2019)

Prevalence of symptoms in female Fabry disease patients: a case-control survey
por: Bouwman, Machtelt G., et al.
Publicado: (2012)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus
por: Muenzer, Joseph, et al.
Publicado: (2011)

Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial
por: Wijburg, Frits A., et al.
Publicado: (2015)

Neurocognitive assessments and long-term outcome in an adult with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency
por: Stepien, Karolina M., et al.
Publicado: (2018)

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome
por: Parini, Rossella, et al.
Publicado: (2018)

Follow-up analysis of voice quality in patients with late-onset Pompe disease
por: Szklanny, Krzysztof, et al.
Publicado: (2018)

Congenital Disorders of Glycosylation: What Clinicians Need to Know?
por: Lipiński, Patryk, et al.
Publicado: (2021)

Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021)

On the history of the mps/co operation
por: Madsen, J. H. B
Publicado: (1973)

The new control system for the MPS - an interim report
por: Asseo, E, et al.
Publicado: (1974)

Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations
por: Wraith, James E., et al.
Publicado: (2013)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Weaknesses of the MPS
por: Holzer, B
Publicado: (2009)

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2011)

Hardware to drive CAMAC systems in MPS
por: Silverman, A, et al.
Publicado: (1974)

Molecular basis underlying resistance to Mps1/TTK inhibitors
por: Koch, A, et al.
Publicado: (2016)

Desoription of the Work in the MPS Division
por: Germain, P, et al.
Publicado: (1961)

Description of the work in the MPS division
por: Germain, P, et al.
Publicado: (1967)

MPS VII – Extending the classical phenotype
por: Oldham, A., et al.
Publicado: (2022)

Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency
por: van Maldegem, Bianca T., et al.
Publicado: (2010)

Voice alterations in patients with Morquio A syndrome
por: Szklanny, Krzysztof, et al.
Publicado: (2017)

Congenital disorders of glycosylation: Prevalence, incidence and mutational spectrum in the Polish population
por: Lipiński, Patryk, et al.
Publicado: (2021)

Treatment trials in Niemann-Pick type C disease
por: Sitarska, Dominika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hvbujenmdt9a4n9obbqmmp3mf